Drug intelligence / Profile preview

amlodipine + valsartan + atorvastatin

Development stage
Phase 1
Lead developer
HK inno.N Corporation
Modality
Small Molecules
Administration
Oral
01

Overview

Amlodipine + valsartan + atorvastatin is a fixed-dose combination of three small molecule drugs used primarily for the management of cardiovascular risk factors. Amlodipine is a calcium channel blocker that relaxes blood vessels and reduces the workload on the heart by inhibiting calcium influx into vascular smooth muscle and cardiac muscle cells. Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to its receptor, leading to vasodilation and reduced blood pressure. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis in the liver. The combination targets hypertension, dyslipidemia, and overall cardiovascular risk reduction[1][2][3][5].

Brand names
Exlow T
Other names
CJ30061CJ-30061CJ 30061
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on amlodipine + valsartan + atorvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + valsartan + atorvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call